4DFF

The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia

Summary for 4DFF

Entry DOI	10.2210/pdb4dff/pdb
Descriptor	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A, MAGNESIUM ION, ZINC ION, ... (5 entities in total)
Functional Keywords	zn binding, mg binding, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
Biological source	Homo sapiens (human)
Cellular location	Cytoplasm: Q9Y233
Total number of polymer chains	2
Total formula weight	81487.75
Authors	Ho, G.D.,Seganish, W.M.,Bercovici, A.,Tulshian, D.,Greenlee, W.J.,Van Rijn, R.,Hruza, A.,Xiao, L.,Rindgen, D.,Mullins, D.,Guzzi, M.,Zhang, X.,Bleichardt, C.,Hodgson, R. (deposition date: 2012-01-23, release date: 2012-03-14, Last modification date: 2012-04-04)
Primary citation	Ho, G.D.,Michael Seganish, W.,Bercovici, A.,Tulshian, D.,Greenlee, W.J.,Van Rijn, R.,Hruza, A.,Xiao, L.,Rindgen, D.,Mullins, D.,Guzzi, M.,Zhang, X.,Bleickardt, C.,Hodgson, R. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Bioorg.Med.Chem.Lett., 22:2585-2589, 2012 Cited by PubMed: 22377514 DOI: 10.1016/j.bmcl.2012.01.113 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.11 Å)

Structure validation